nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprostadil—SLCO3A1—nephron—nephrolithiasis	0.0464	0.224	CbGeAlD
Alprostadil—PTGIR—Endothelin Pathways—ADCY10—nephrolithiasis	0.0299	0.0661	CbGpPWpGaD
Alprostadil—Atrioventricular block second degree—Hydrochlorothiazide—nephrolithiasis	0.0254	0.0746	CcSEcCtD
Alprostadil—Stiffness—Hydrochlorothiazide—nephrolithiasis	0.0191	0.0561	CcSEcCtD
Alprostadil—PTGER1—renal system—nephrolithiasis	0.0167	0.0807	CbGeAlD
Alprostadil—PTGER1—kidney—nephrolithiasis	0.0162	0.078	CbGeAlD
Alprostadil—Leg pain—Hydrochlorothiazide—nephrolithiasis	0.0157	0.0462	CcSEcCtD
Alprostadil—Trauma—Hydrochlorothiazide—nephrolithiasis	0.0152	0.0448	CcSEcCtD
Alprostadil—Serum creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.0118	0.0347	CcSEcCtD
Alprostadil—Respiratory distress—Hydrochlorothiazide—nephrolithiasis	0.0114	0.0336	CcSEcCtD
Alprostadil—PTGIR—renal system—nephrolithiasis	0.0103	0.0499	CbGeAlD
Alprostadil—PTGIR—kidney—nephrolithiasis	0.00998	0.0482	CbGeAlD
Alprostadil—SLCO2A1—nephron tubule—nephrolithiasis	0.00993	0.048	CbGeAlD
Alprostadil—Ventricular fibrillation—Hydrochlorothiazide—nephrolithiasis	0.00947	0.0279	CcSEcCtD
Alprostadil—SLCO2A1—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00939	0.0207	CbGpPWpGaD
Alprostadil—Feeling hot—Hydrochlorothiazide—nephrolithiasis	0.00924	0.0272	CcSEcCtD
Alprostadil—SLCO3A1—renal system—nephrolithiasis	0.00911	0.044	CbGeAlD
Alprostadil—ABCC5—nephron tubule—nephrolithiasis	0.00908	0.0439	CbGeAlD
Alprostadil—SLCO2A1—renal system—nephrolithiasis	0.00903	0.0436	CbGeAlD
Alprostadil—SLCO3A1—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.0089	0.0197	CbGpPWpGaD
Alprostadil—SLCO3A1—kidney—nephrolithiasis	0.00881	0.0426	CbGeAlD
Alprostadil—Numbness—Hydrochlorothiazide—nephrolithiasis	0.00875	0.0257	CcSEcCtD
Alprostadil—SLCO2A1—kidney—nephrolithiasis	0.00873	0.0421	CbGeAlD
Alprostadil—SLCO2A1—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00859	0.019	CbGpPWpGaD
Alprostadil—SLCO2A1—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00859	0.019	CbGpPWpGaD
Alprostadil—SLCO3A1—cortex of kidney—nephrolithiasis	0.00858	0.0414	CbGeAlD
Alprostadil—SLCO2A1—cortex of kidney—nephrolithiasis	0.0085	0.041	CbGeAlD
Alprostadil—Sensory loss—Hydrochlorothiazide—nephrolithiasis	0.00838	0.0246	CcSEcCtD
Alprostadil—SLCO3A1—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00814	0.018	CbGpPWpGaD
Alprostadil—SLCO3A1—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00814	0.018	CbGpPWpGaD
Alprostadil—Musculoskeletal stiffness—Hydrochlorothiazide—nephrolithiasis	0.00809	0.0238	CcSEcCtD
Alprostadil—Hypercholesterolaemia—Hydrochlorothiazide—nephrolithiasis	0.00767	0.0226	CcSEcCtD
Alprostadil—Hyperkalaemia—Hydrochlorothiazide—nephrolithiasis	0.00713	0.021	CcSEcCtD
Alprostadil—Wheezing—Hydrochlorothiazide—nephrolithiasis	0.00705	0.0207	CcSEcCtD
Alprostadil—Ecchymosis—Hydrochlorothiazide—nephrolithiasis	0.00656	0.0193	CcSEcCtD
Alprostadil—SLCO2A1—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00651	0.0144	CbGpPWpGaD
Alprostadil—SLCO2A1—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00651	0.0144	CbGpPWpGaD
Alprostadil—SLCO2B1—renal system—nephrolithiasis	0.00646	0.0312	CbGeAlD
Alprostadil—ABCC4—nephron tubule—nephrolithiasis	0.00629	0.0304	CbGeAlD
Alprostadil—SLCO2B1—kidney—nephrolithiasis	0.00625	0.0302	CbGeAlD
Alprostadil—SLCO3A1—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00617	0.0136	CbGpPWpGaD
Alprostadil—SLCO3A1—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00617	0.0136	CbGpPWpGaD
Alprostadil—Diabetes mellitus—Hydrochlorothiazide—nephrolithiasis	0.00605	0.0178	CcSEcCtD
Alprostadil—SLCO2A1—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00605	0.0134	CbGpPWpGaD
Alprostadil—SLCO2A1—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00605	0.0134	CbGpPWpGaD
Alprostadil—Swelling—Hydrochlorothiazide—nephrolithiasis	0.00597	0.0176	CcSEcCtD
Alprostadil—ABCC5—Defective B3GAT3 causes JDSSDHD—SLC26A1—nephrolithiasis	0.00594	0.0131	CbGpPWpGaD
Alprostadil—PTGER2—G alpha (s) signalling events—PTH—nephrolithiasis	0.00583	0.0129	CbGpPWpGaD
Alprostadil—Nasal congestion—Hydrochlorothiazide—nephrolithiasis	0.00578	0.017	CcSEcCtD
Alprostadil—SLCO3A1—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00574	0.0127	CbGpPWpGaD
Alprostadil—SLCO3A1—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00574	0.0127	CbGpPWpGaD
Alprostadil—Injury—Hydrochlorothiazide—nephrolithiasis	0.00573	0.0168	CcSEcCtD
Alprostadil—ABCC4—renal system—nephrolithiasis	0.00572	0.0276	CbGeAlD
Alprostadil—ABCC4—kidney—nephrolithiasis	0.00553	0.0267	CbGeAlD
Alprostadil—SLCO2A1—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00539	0.0119	CbGpPWpGaD
Alprostadil—ABCC4—cortex of kidney—nephrolithiasis	0.00539	0.026	CbGeAlD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00535	0.0118	CbGpPWpGaD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00535	0.0118	CbGpPWpGaD
Alprostadil—Pain in extremity—Hydrochlorothiazide—nephrolithiasis	0.00527	0.0155	CcSEcCtD
Alprostadil—SLCO2B1—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00516	0.0114	CbGpPWpGaD
Alprostadil—SLCO3A1—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00511	0.0113	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00508	0.0112	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00508	0.0112	CbGpPWpGaD
Alprostadil—ABCC5—NRF2 pathway—SLC2A9—nephrolithiasis	0.00504	0.0111	CbGpPWpGaD
Alprostadil—Blood creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.00493	0.0145	CcSEcCtD
Alprostadil—Hypokalaemia—Hydrochlorothiazide—nephrolithiasis	0.00479	0.0141	CcSEcCtD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00477	0.0105	CbGpPWpGaD
Alprostadil—SLCO2B1—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00472	0.0104	CbGpPWpGaD
Alprostadil—SLCO2B1—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00472	0.0104	CbGpPWpGaD
Alprostadil—Influenza—Hydrochlorothiazide—nephrolithiasis	0.00455	0.0134	CcSEcCtD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00452	0.00999	CbGpPWpGaD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00436	0.00964	CbGpPWpGaD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00436	0.00964	CbGpPWpGaD
Alprostadil—PTGER1—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00429	0.00947	CbGpPWpGaD
Alprostadil—Upper respiratory tract infection—Hydrochlorothiazide—nephrolithiasis	0.00423	0.0124	CcSEcCtD
Alprostadil—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.0042	0.0124	CcSEcCtD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00414	0.00914	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00414	0.00914	CbGpPWpGaD
Alprostadil—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.00411	0.0121	CcSEcCtD
Alprostadil—Acute coronary syndrome—Hydrochlorothiazide—nephrolithiasis	0.004	0.0118	CcSEcCtD
Alprostadil—Renal failure—Hydrochlorothiazide—nephrolithiasis	0.00399	0.0117	CcSEcCtD
Alprostadil—Myocardial infarction—Hydrochlorothiazide—nephrolithiasis	0.00398	0.0117	CcSEcCtD
Alprostadil—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.00395	0.0116	CcSEcCtD
Alprostadil—PTGIR—G alpha (s) signalling events—PTH—nephrolithiasis	0.00394	0.0087	CbGpPWpGaD
Alprostadil—Haematuria—Hydrochlorothiazide—nephrolithiasis	0.00387	0.0114	CcSEcCtD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00384	0.00847	CbGpPWpGaD
Alprostadil—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.00381	0.0112	CcSEcCtD
Alprostadil—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.00371	0.0109	CcSEcCtD
Alprostadil—Rhinitis—Hydrochlorothiazide—nephrolithiasis	0.00365	0.0107	CcSEcCtD
Alprostadil—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.00363	0.0107	CcSEcCtD
Alprostadil—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.00362	0.0106	CcSEcCtD
Alprostadil—SLCO2B1—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00358	0.0079	CbGpPWpGaD
Alprostadil—SLCO2B1—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00358	0.0079	CbGpPWpGaD
Alprostadil—PTGER2—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00355	0.00784	CbGpPWpGaD
Alprostadil—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.00351	0.0103	CcSEcCtD
Alprostadil—ABCC4—NRF2 pathway—SLC2A9—nephrolithiasis	0.0035	0.00772	CbGpPWpGaD
Alprostadil—Flushing—Hydrochlorothiazide—nephrolithiasis	0.00338	0.00994	CcSEcCtD
Alprostadil—SLCO2B1—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00333	0.00735	CbGpPWpGaD
Alprostadil—SLCO2B1—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00333	0.00735	CbGpPWpGaD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00331	0.0073	CbGpPWpGaD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00331	0.0073	CbGpPWpGaD
Alprostadil—ABCC5—Carbohydrate metabolism—SLC26A1—nephrolithiasis	0.00319	0.00704	CbGpPWpGaD
Alprostadil—Erythema—Hydrochlorothiazide—nephrolithiasis	0.00317	0.00932	CcSEcCtD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00314	0.00692	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00314	0.00692	CbGpPWpGaD
Alprostadil—PTGER1—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.0031	0.00685	CbGpPWpGaD
Alprostadil—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.00308	0.00906	CcSEcCtD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00308	0.00679	CbGpPWpGaD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00308	0.00679	CbGpPWpGaD
Alprostadil—Back pain—Hydrochlorothiazide—nephrolithiasis	0.00307	0.00902	CcSEcCtD
Alprostadil—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00305	0.00897	CcSEcCtD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00304	0.00671	CbGpPWpGaD
Alprostadil—SLCO2B1—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00296	0.00655	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00294	0.0065	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00294	0.0065	CbGpPWpGaD
Alprostadil—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.00293	0.00862	CcSEcCtD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00292	0.00644	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00292	0.00644	CbGpPWpGaD
Alprostadil—Syncope—Hydrochlorothiazide—nephrolithiasis	0.00284	0.00836	CcSEcCtD
Alprostadil—ABCC5—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00281	0.00621	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00281	0.00621	CbGpPWpGaD
Alprostadil—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.00279	0.0082	CcSEcCtD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00277	0.00612	CbGpPWpGaD
Alprostadil—Cough—Hydrochlorothiazide—nephrolithiasis	0.00277	0.00814	CcSEcCtD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00274	0.00605	CbGpPWpGaD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00274	0.00605	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—RGS14—nephrolithiasis	0.00268	0.00592	CbGpPWpGaD
Alprostadil—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.00267	0.00784	CcSEcCtD
Alprostadil—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.00264	0.00776	CcSEcCtD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00262	0.00579	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.0026	0.00574	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.0026	0.00574	CbGpPWpGaD
Alprostadil—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00259	0.00761	CcSEcCtD
Alprostadil—Shock—Hydrochlorothiazide—nephrolithiasis	0.00255	0.00749	CcSEcCtD
Alprostadil—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00253	0.00745	CcSEcCtD
Alprostadil—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00253	0.00743	CcSEcCtD
Alprostadil—ABCC5—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00251	0.00554	CbGpPWpGaD
Alprostadil—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.0025	0.00736	CcSEcCtD
Alprostadil—PTGER2—Signaling by GPCR—RGS14—nephrolithiasis	0.00243	0.00537	CbGpPWpGaD
Alprostadil—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.00242	0.00711	CcSEcCtD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.0024	0.0053	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.0024	0.0053	CbGpPWpGaD
Alprostadil—PTGER1—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.0024	0.00529	CbGpPWpGaD
Alprostadil—PTGIR—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.0024	0.00529	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—CHRM3—nephrolithiasis	0.00232	0.00511	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00229	0.00506	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00229	0.00506	CbGpPWpGaD
Alprostadil—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00228	0.0067	CcSEcCtD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.00224	0.00494	CbGpPWpGaD
Alprostadil—Pain—Hydrochlorothiazide—nephrolithiasis	0.00221	0.00651	CcSEcCtD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00219	0.00484	CbGpPWpGaD
Alprostadil—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00213	0.00627	CcSEcCtD
Alprostadil—PTGER2—GPCR ligand binding—PTH—nephrolithiasis	0.00212	0.00468	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00208	0.00459	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00205	0.00454	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00205	0.00454	CbGpPWpGaD
Alprostadil—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00205	0.00602	CcSEcCtD
Alprostadil—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00205	0.00602	CcSEcCtD
Alprostadil—ABCC4—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00195	0.00431	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00195	0.00431	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—DGKH—nephrolithiasis	0.00193	0.00427	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—SLC7A9—nephrolithiasis	0.00193	0.00427	CbGpPWpGaD
Alprostadil—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00186	0.00546	CcSEcCtD
Alprostadil—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00183	0.00538	CcSEcCtD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00182	0.00402	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00182	0.00402	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—RGS14—nephrolithiasis	0.00181	0.004	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—RGS14—nephrolithiasis	0.00181	0.004	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—DGKH—nephrolithiasis	0.00181	0.004	CbGpPWpGaD
Alprostadil—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00177	0.00521	CcSEcCtD
Alprostadil—ABCC5—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00174	0.00384	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00174	0.00384	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00174	0.00384	CbGpPWpGaD
Alprostadil—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00171	0.00503	CcSEcCtD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00169	0.00373	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00169	0.00373	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—ADCY10—nephrolithiasis	0.00169	0.00373	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—RGS14—nephrolithiasis	0.00164	0.00363	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—RGS14—nephrolithiasis	0.00164	0.00363	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—DGKH—nephrolithiasis	0.00164	0.00363	CbGpPWpGaD
Alprostadil—Rash—Hydrochlorothiazide—nephrolithiasis	0.00163	0.0048	CcSEcCtD
Alprostadil—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00163	0.00479	CcSEcCtD
Alprostadil—Headache—Hydrochlorothiazide—nephrolithiasis	0.00162	0.00477	CcSEcCtD
Alprostadil—ABCC5—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00162	0.00357	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00162	0.00357	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00159	0.00351	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00159	0.00351	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—CHRM3—nephrolithiasis	0.00156	0.00345	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—CHRM3—nephrolithiasis	0.00156	0.00345	CbGpPWpGaD
Alprostadil—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00154	0.00452	CcSEcCtD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00151	0.00333	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00151	0.00333	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00144	0.00318	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00144	0.00318	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—RGS14—nephrolithiasis	0.00144	0.00317	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—PTH—nephrolithiasis	0.00143	0.00316	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—PTH—nephrolithiasis	0.00143	0.00316	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—CHRM3—nephrolithiasis	0.00131	0.00289	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—DGKH—nephrolithiasis	0.00122	0.0027	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—DGKH—nephrolithiasis	0.00122	0.0027	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.0012	0.00266	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.0012	0.00266	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.0012	0.00266	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—PTH—nephrolithiasis	0.0012	0.00264	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—CHRM3—nephrolithiasis	0.00119	0.00262	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—SLC7A9—nephrolithiasis	0.00115	0.00255	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—DGKH—nephrolithiasis	0.00115	0.00255	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00115	0.00254	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ADCY10—nephrolithiasis	0.00114	0.00252	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ADCY10—nephrolithiasis	0.00114	0.00252	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00112	0.00247	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00112	0.00247	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—DGKH—nephrolithiasis	0.00111	0.00245	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—DGKH—nephrolithiasis	0.00111	0.00245	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—PTH—nephrolithiasis	0.00109	0.0024	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GRHPR—nephrolithiasis	0.000998	0.0022	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000998	0.0022	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000998	0.0022	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—RGS14—nephrolithiasis	0.000971	0.00214	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—RGS14—nephrolithiasis	0.000971	0.00214	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000971	0.00214	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—DGKH—nephrolithiasis	0.000971	0.00214	CbGpPWpGaD
Alprostadil—ABCC5—Disease—SLC26A1—nephrolithiasis	0.000903	0.002	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—AGXT—nephrolithiasis	0.00089	0.00197	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000884	0.00195	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000884	0.00195	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—PTH—nephrolithiasis	0.000808	0.00179	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—PTH—nephrolithiasis	0.000808	0.00179	CbGpPWpGaD
Alprostadil—ABCC5—Disease—ATP6V0A4—nephrolithiasis	0.000805	0.00178	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—CHRM3—nephrolithiasis	0.000803	0.00177	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—CHRM3—nephrolithiasis	0.000803	0.00177	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000798	0.00176	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—SLC26A1—nephrolithiasis	0.000757	0.00167	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—APRT—nephrolithiasis	0.000757	0.00167	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PTH—nephrolithiasis	0.000734	0.00162	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PTH—nephrolithiasis	0.000734	0.00162	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CHRM3—nephrolithiasis	0.000702	0.00155	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—DGKH—nephrolithiasis	0.000656	0.00145	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000656	0.00145	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000656	0.00145	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—DGKH—nephrolithiasis	0.000656	0.00145	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PTH—nephrolithiasis	0.000642	0.00142	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—AQP1—nephrolithiasis	0.000539	0.00119	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CHRM3—nephrolithiasis	0.000488	0.00108	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CHRM3—nephrolithiasis	0.000474	0.00105	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CHRM3—nephrolithiasis	0.000474	0.00105	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PTH—nephrolithiasis	0.000434	0.000958	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PTH—nephrolithiasis	0.000434	0.000958	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—SPP1—nephrolithiasis	0.000322	0.000712	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—SPP1—nephrolithiasis	0.000218	0.000481	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SPP1—nephrolithiasis	0.000218	0.000481	CbGpPWpGaD
